SCHEMBL6322333

SCHEMBL6322333

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4cccc(F)c4)c32)c(C)c1C(=O)N1CCC(O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.56
FLT1 P17948 2/20 0.56
PDGFRB P09619 8/20 0.48
FGFR1 P11362 7/20 0.48
ALK Q9UM73 3/20 0.47
TLK2 Q86UE8 4/20 0.45
MET P08581 4/20 0.43
PTK2B Q14289 2/20 0.43
MEN1 O00255 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
EGFR P00533 2/20 0.43
PDGFRA P16234 2/20 0.43
PRKAA2 P54646 5/20 0.43
PRKAA1 Q13131 5/20 0.43
FLT3 P36888 4/20 0.43
ABL1 P00519 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320490 0.95 KDR (0.53) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6321855 0.95 KDR (0.53) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6323810 0.92 KDR (0.53) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6328542 0.91 KDR (0.57) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6328538 0.91 KDR (0.57) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6322625 0.90 KDR (0.60) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6329110 0.87 KDR (0.48) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6319478 0.87 KDR (0.43) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6319920 0.86 PRKAA2 (0.47) KDRFLT1PDGFRBFGFR1ALK
SCHEMBL6322488 0.86 KDR (0.49) KDRFLT1PDGFRBFGFR1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FLT1 1811/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FLT1 1811/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.